Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD) Following Positive HIV Trial Results

Gilead Sciences Inc. (NASDAQ:GILD) ranks among the best set-it-and-forget-it stocks to buy right now. Cantor Fitzgerald restated an Overweight rating and a $155 price target for Gilead Sciences Inc. (NASDAQ:GILD) on June 9, following the company’s clinical research findings.

Gilead Sciences Inc. (NASDAQ:GILD), in collaboration with Merck, revealed solid top-line results from the phase 3 ISLEND-1 and ISLEND-2 studies of weekly islatravir/lenacapavir for HIV medication. Additionally, the companies reported negative findings from the EVOKE-03 study comparing Trodelvy with Keytruda versus Keytruda monotherapy in patients with first-line PD-L1 non-small cell lung cancer.

Moreover, on June 8, RBC Capital reaffirmed its $122 Sector Perform rating for Gilead Sciences Inc. (NASDAQ:GILD). The firm made remarks regarding the company’s position in the domain of in vivo CAR-T treatment.

The firm added that in vivo CAR-T represents a possible risk to a sector that is estimated to account for 10-15% of Gilead’s potential revenue. According to RBC Capital, Gilead Sciences Inc. (NASDAQ:GILD) has begun to build promising technology in the field with differentiating features and a wide approach that incorporates current experience.

Gilead Sciences Inc. (NASDAQ:GILD) is a drug manufacturer that develops medicines for unmet medical needs. The company provides treatments for HIV-1, chronic hepatitis C, primary biliary cholangitis, chronic hepatitis B, and serious invasive fungal infections. It also offers T-cell and CAR T-cell therapies for adult patients, intravenous injections, and treatments for COVID-19.

While we acknowledge the risk and potential of GILD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GILD and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1